Lupus News

Liquid biopsy could provide enhanced information about chimeric antigen receptor T-cell therapy compared with normally used DNA, RNA and protein assays, according to findings published in Journal for ImmunoTherapy of Cancer.

Pregnant patients with lupus or antiphospholipid syndrome have a higher risk for preterm birth, although immune-mediated inflammatory diseases in general are “only weakly associated” with adverse pregnancy outcomes, according to data.

The FDA has approved a supplemental new drug application for an Acthar Gel injector for the treatment of several chronic and acute inflammatory and autoimmune conditions, according to the manufacturer.

The FDA has cleared an investigational new drug application for an allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of systemic lupus erythematosus with lupus nephritis, according to the manufacturer.

Single injections of CD19 chimeric antigen receptor T-cell therapy brought long-lasting remission to 15 patients with three different autoimmune diseases, according to data published in The New England Journal of Medicine.

I am thrilled to introduce our cover story this month, “‘Exploring the Power of Their Mind’: Data May Offer Clues to Harnessing the Placebo Effect,” to the readers of Healio Rheumatology. I say this for several reasons.

SCOTTSDALE, Ariz. — A novel therapeutic approach targeting the neonatal fragment crystallizable receptor may have implications across a number of rheumatology disease states, according to a speaker.

SCOTTSDALE, Ariz. — Chimeric antigen receptor T-cell therapy had “unprecedented” and “astonishing” results in lupus, but whether it will truly revolutionize rheumatology care remains to be seen, according to a speaker.

Remission and low disease activity can discriminate between patients taking active drug vs. placebo in clinical trials and are linked to health-related quality of life, according to data in Arthritis Care & Research.

Apoptotic lymphocytes in peripheral blood may be a meaningful factor in the prognosis of juvenile-onset systemic lupus erythematosus, as well as a predictor of disease activity, according to data published in Pediatric Rheumatology.